If the EMA also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.
Despite some setbacks, great strides have been made in the past three years towards clinical trial transparency, but a great deal of information still remains hidden from policymakers, clinicians, and patients, and if the European Medicines Agency (EMA) also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.
EMA’s management board is due to meet on June 12 to finalize the policy, and some observers have expressed concern over recent weeks that the Agency has decided to backtrack on its decision for public access to clinical trial data.
On the plus side, even with a “watered down policy”, EMA will be making visible vast quantities of new regulatory information about randomized controlled trials of drugs and other types of interventional or observational clinical research methodologies, noted the BMJ’s Head of Research, Trish Groves, and European Research Editor, Wim Weber.
However, if the new European policies for proactive disclosure close the EMA window that has been allowing ad hoc retroactive access to older clinical study reports and data, then decision-makers will be even less well informed when making decisions about current treatments, they noted.
“That is why AllTrials continues to campaign for all clinical trials to be registered and all results reported. The research, advocacy, haggling, and politics must go on,” the authors wrote.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.